We are live on ! Find out more
MGNX icon

MacroGenics

130 hedge funds and large institutions have $796M invested in MacroGenics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 57 increasing their positions, 37 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

176% more call options, than puts

Call options by funds: $4.98M | Put options by funds: $1.81M

54% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 37

5.48% more ownership

Funds ownership: 90.6%96.08% (+5.5%)

0% more capital invested

Capital invested by funds: $795M → $796M (+$339K)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

17% less funds holding

Funds holding: 157130 (-27)

59% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 39

Holders
130
Holders Change
-27
Holders Change %
-17.2%
% of All Funds
2.82%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
57
Reduced
37
Closed
39
Calls
$4.98M
Puts
$1.81M
Net Calls
+$3.17M
Net Calls Change
-$1.56M
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$7.56M -$19M -1,105,677 -71%
Renaissance Technologies
27
Renaissance Technologies
New York
$7.2M -$6.86M -399,300 -48%
Man Group
28
Man Group
United Kingdom
$5.66M +$1.22M +70,874 +27%
PAM
29
Panagora Asset Management
Massachusetts
$5.1M +$5.16M +300,587 New
RSCM
30
Rock Springs Capital Management
Maryland
$5.09M
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$5.06M -$6.44M -374,805 -56%
Macquarie Group
32
Macquarie Group
Australia
$4.67M +$258K +15,000 +6%
Charles Schwab
33
Charles Schwab
California
$4.46M +$408K +23,779 +10%
Principal Financial Group
34
Principal Financial Group
Iowa
$3.98M +$892K +51,952 +28%
GIM
35
Granahan Investment Management
Massachusetts
$3.64M -$229K -13,304 -6%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.4M +$556K +32,380 +19%
EP
37
Eversept Partners
New York
$3.23M +$3.27M +190,623 New
Axa
38
Axa
France
$3.03M +$1.89M +110,026 +161%
Allianz Asset Management
39
Allianz Asset Management
Germany
$2.52M -$83K -4,830 -3%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$2.42M +$1.6M +93,157 +187%
FI
41
Fosun International
China
$2.19M +$928K +54,000 +70%
Bank of America
42
Bank of America
North Carolina
$2.14M -$1.6M -93,078 -42%
Squarepoint
43
Squarepoint
New York
$2.03M +$11.4K +662 +0.6%
Goldman Sachs
44
Goldman Sachs
New York
$1.99M +$10.8K +630 +0.5%
Victory Capital Management
45
Victory Capital Management
Texas
$1.81M +$63K +3,670 +4%
Citigroup
46
Citigroup
New York
$1.76M +$1.5M +87,479 +539%
AA
47
ALPS Advisors
Colorado
$1.73M -$261K -15,179 -13%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$1.68M +$431K +25,093 +34%
VIA
49
Vident Investment Advisory
Georgia
$1.61M -$169K -9,856 -9%
Deutsche Bank
50
Deutsche Bank
Germany
$1.58M -$2.78M -161,955 -63%

MGNX Hedge Fund Activity: Q2 2019 in Review

130 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q2 2019, worth a combined $796M — up 0.04% from $795M a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of MGNX and 16 opened new positions — a net loss of 23 holders — while 37 trimmed existing stakes and 57 added.

The largest buyer was Invesco, adding an estimated $76.7M. The largest seller was Point72 Asset Management, cutting an estimated $19M.

  • 130 institutional investors held MacroGenics (MGNX) as of Q2 2019, down from 157 in Q1 2019.
  • Funds reported $796M of MacroGenics stock for Q2 2019, up 0.04% quarter-over-quarter.
  • 16 funds opened new MacroGenics positions in Q2 2019 and 39 closed out, a net change of -23 holders.
  • The largest MacroGenics buyer in Q2 2019 was Invesco, an estimated $76.7M added.
  • The largest MacroGenics seller in Q2 2019 was Point72 Asset Management, an estimated $19M sold.

Based on aggregated 13F filings for Q2 2019.